{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:00:59Z","timestamp":1774267259943,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10096-021-04187-5","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T17:48:06Z","timestamp":1613756886000},"page":"1767-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stepwise selection of mutation conferring fluroquinolone resistance: multisite MDR-TB cohort study"],"prefix":"10.1007","volume":"40","author":[{"given":"Jingtao","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongtan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"4187_CR1","unstructured":"World Health Organization (2019) Global tuberculosis report 2019. Geneva: World Health Organization. WHO\/HTM\/TB\/2019.13"},{"key":"4187_CR2","first-page":"348","volume":"76","author":"C Xu","year":"2018","unstructured":"Xu C, Pang Y, Li R, Ruan Y, Wang L, Chen M, Zhang H (2018) Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Inf Secur 76:348\u2013353","journal-title":"J Inf Secur"},{"key":"4187_CR3","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019","unstructured":"World Health Organization (2019) WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, Geneva"},{"key":"4187_CR4","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3201\/eid2509.190105","volume":"25","author":"PK Singh","year":"2019","unstructured":"Singh PK, Jain A (2019) Limited scope of shorter drug regimen for MDR TB caused by high resistance to fluoroquinolone. Emerg Infect Dis 25:1760\u20131762","journal-title":"Emerg Infect Dis"},{"key":"4187_CR5","doi-asserted-by":"crossref","unstructured":"Pang Y, Zhang Z, Wang Y, Wang S, Song Y, Zhao B, Zhou Y, Ou X, Li Q, Xia H, Zheng Y, Fang X, Zhao Y (2017) Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother 61","DOI":"10.1128\/AAC.02170-16"},{"key":"4187_CR6","doi-asserted-by":"crossref","unstructured":"Liu Y, Gao M, Du J, Wang L, Gao J, Shu W, Wang Y, Xue Z, Li L, Pang Y (2020) Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis","DOI":"10.1093\/cid\/ciaa1002"},{"key":"4187_CR7","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1128\/AAC.01049-15","volume":"60","author":"JY Chien","year":"2016","unstructured":"Chien JY, Chiu WY, Chien ST, Chiang CJ, Yu CJ, Hsueh PR (2016) Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 60:2090\u20132096","journal-title":"Antimicrob Agents Chemother"},{"key":"4187_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/cid\/ciu572","volume":"59","author":"JP Cegielski","year":"2014","unstructured":"Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S (2014) Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59:1049\u20131063","journal-title":"Clin Infect Dis"},{"key":"4187_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1183\/09031936.00176610","volume":"38","author":"AD Pranger","year":"2011","unstructured":"Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW (2011) Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 38:888\u2013894","journal-title":"Eur Respir J"},{"key":"4187_CR10","first-page":"2124","volume":"75","author":"M Ortiz-Padilla","year":"2020","unstructured":"Ortiz-Padilla M, Diaz-Diaz S, Machuca J, Tejada-Gonzalez A, Recacha E, Docobo-Perez F, Pascual A, Rodriguez-Martinez JM (2020) Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacin. J Antimicrob Chemother 75:2124\u20132132","journal-title":"J Antimicrob Chemother"},{"key":"4187_CR11","doi-asserted-by":"crossref","unstructured":"Huo F, Ma Y, Li S, Xue Y, Shang Y, Dong L, Li Y, Pang Y (2020) Specific gyrA gene mutations correlate with high prevalence of discordant levofloxacin resistance in Mycobacterium tuberculosis isolates from Beijing, China. J Mol Diagn","DOI":"10.1101\/841031"},{"key":"4187_CR12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jac\/dkx110","volume":"72","author":"T Luo","year":"2017","unstructured":"Luo T, Yuan J, Peng X, Yang G, Mi Y, Sun C, Wang C, Zhang C, Bao L (2017) Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. J Antimicrob Chemother 72:1893\u20131900","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04187-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T14:45:07Z","timestamp":1626878707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04187-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4187"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04187-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Chest Hospital, Capital Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The participant signed a written informed consent to agree with the anonymous use of clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}